Demographics |
Age, median (25th–75th percentile), years |
64 (56–72) |
64 (56–72) |
63 (55–71) |
63 (55–71) |
65 (57–73) |
65 (57–73) |
Age ≥ 75 years, n (%) |
955 (17.1) |
1024 (18.6) |
420 (14.6) |
460 (16.2) |
535 (19.8) |
564 (21.2) |
Female gender, n (%) |
1746 (31.3) |
1746 (31.8) |
706 (24.6) |
716 (25.2) |
1040 (38.4) |
1030 (38.8) |
Body weight <60 kg, n (%) |
398 (7.2) |
389 (7.1) |
165 (5.8) |
172 (6.1) |
233 (8.6) |
217 (8.2) |
Body mass index, median (25th–75th percentile), kg/m2
|
27.5 (24.8–30.8) |
27.4 (24.8–30.5) |
27.5 (24.9–30.8) |
27.5 (24.9–30.5) |
27.5 (24.7–30.6) |
27.3 (24.6–30.5) |
GRACE risk score nomogram |
130 (112–150) |
130 (112–149) |
128 (110–145) |
127 (110–145) |
133 (114–154) |
134 (116–153) |
Cardiovascular risk factors, n (%) |
Current smoking |
1636 (29.4) |
1640 (29.9) |
1000 (34.8) |
960 (33.8) |
636 (23.6) |
680 (25.6) |
Hypertension |
3915 (70.2) |
3835 (69.8) |
1881 (65.5) |
1886 (66.4) |
2034 (75.3) |
1949 (73.4) |
Dyslipidaemia |
2885 (51.8) |
2852 (51.9) |
1515 (52.8) |
1569 (55.2) |
1370 (50.7) |
1283 (48.3) |
Diabetes mellitus |
1608 (28.9) |
1520 (27.7) |
756 (26.3) |
747 (26.3) |
852 (31.6) |
773 (29.1) |
Medical history, n (%) |
Angina pectoris |
2932 (52.6) |
2890 (52.6) |
1337 (46.5) |
1356 (47.7) |
1595 (59.1) |
1534 (57.8) |
Myocardial infarction |
1400 (25.1) |
1410 (25.7) |
609 (21.2) |
608 (21.4) |
791 (29.3) |
802 (30.2) |
Congestive heart failure |
397 (7.1) |
429 (7.8) |
99 (3.4) |
103 (3.6) |
298 (11.0) |
326 (12.3) |
Percutaneous coronary intervention (PCI) |
944 (16.9) |
918 (16.7) |
537 (18.7) |
517 (18.2) |
407 (15.1) |
401 (15.1) |
Coronary artery bypass graft (CABG) |
434 (7.8) |
474 (8.6) |
214 (7.4) |
218 (7.7) |
220 (8.1) |
256 (9.6) |
Transient ischaemic attack |
185 (3.3) |
189 (3.4) |
82 (2.9) |
74 (2.6) |
103 (3.8) |
115 (4.3) |
Non-hemorrhagic stroke |
246 (4.4) |
243 (4.4) |
81 (2.8) |
98 (3.5) |
165 (6.1) |
145 (5.5) |
Peripheral arterial disease |
400 (7.2) |
413 (7.5) |
174 (6.1) |
204 (7.2) |
226 (8.4) |
209 (7.9) |
Chronic renal disease |
273 (4.9) |
279 (5.1) |
117 (4.1) |
108 (3.8) |
156 (5.8) |
171 (6.4) |
Physical findings, median (25th–75th percentile) |
Heart rate (bpm) |
72 (64–80) |
72 (64–81) |
71 (62–80) |
72 (63–80) |
72 (64–82) |
72 (64–82) |
Systolic blood pressure (mmHg) |
135 (120–150) |
134 (120–150) |
135 (120–150) |
135 (120–150) |
134 (120–150) |
132 (120–150) |
Diastolic blood pressure (mmHg) |
80 (70–89) |
80 (70–87) |
80 (70–89) |
80 (70–87) |
80 (70–89) |
80 (70–87) |
Risk indicators, n (%) |
Troponin positive, n (%) |
4356 (80.8) |
4323 (81.3) |
2522 (89.6) |
2486 (89.3) |
1834 (71.3) |
1837 (72.4) |
ST depression (≥1 mm) |
3158 (56.8) |
3201 (58.4) |
1547 (54.0) |
1535 (54.2) |
1611 (59.8) |
1666 (62.8) |
TIMI risk score > 2 |
4838 (89.7) |
4785 (89.8) |
2584 (91.3) |
2566 (91.8) |
2254 (88.0) |
2219 (87.7) |
Type of ACS at discharge, n (%) |
STEMI |
449 (8.1) |
437 (8.0) |
330 (11.5) |
305 (10.7) |
119 (4.4) |
132 (5.0) |
NSTEMI |
3605 (64.8) |
3525 (64.3) |
2045 (71.2) |
2025 (71.3) |
1560 (58.0) |
1500 (56.7) |
UA/other |
1509 (27.1) |
1524 (27.8) |
497 (17.3) |
510 (18.0) |
1012 (37.6) |
1014 (38.3) |
Antithrombotic treatment during index hospitalization, n (%) |
Aspirin |
5386 (96.6) |
5316 (96.8) |
2797 (97.4) |
2779 (97.8) |
2589 (95.9) |
2537 (95.8) |
Unfractionated heparin |
2910 (52.1) |
2856 (51.9) |
1845 (64.2) |
1845 (64.9) |
1065 (39.3) |
1011 (38.0) |
Low molecular weight heparin |
3181 (57.0) |
3084 (56.1) |
1568 (54.6) |
1501 (52.8) |
1613 (59.6) |
1583 (59.6) |
Fondaparinux |
194 (3.5) |
191 (3.5) |
87 (3.0) |
76 (2.7) |
107 (4.0) |
115 (4.3) |
Bivalirudin |
140 (2.5) |
133 (2.4) |
135 (4.7) |
122 (4.3) |
5 (0.2) |
11 (0.4) |
GP IIb/IIIa inhibitor |
1170 (21.0) |
1117 (20.3) |
982 (34.2) |
963 (33.9) |
188 (6.9) |
154 (5.8) |
Other drug from randomization to end of study, n (%) |
Beta-blocker |
4768 (85.4) |
4685 (85.2) |
2536 (88.3) |
2512 (88.4) |
2232 (82.4) |
2173 (81.8) |
ACE-inhibitor and/or ARB |
4693 (84.2) |
4602 (83.8) |
2447 (85.2) |
2433 (85.6) |
2246 (83.2) |
2169 (81.9) |
Statin |
5196 (93.1) |
5109 (92.9) |
2777 (96.7) |
2745 (96.6) |
2419 (89.3) |
2364 (88.9) |
Proton-pump inhibitor |
2776 (49.7) |
2613 (47.5) |
1618 (56.3) |
1536 (54.1) |
1158 (42.8) |
1077 (40.5) |
Calcium channel inhibitor |
1553 (27.8) |
1515 (27.6) |
720 (25.1) |
723 (25.4) |
833 (30.8) |
792 (29.8) |
Diuretic |
2393 (42.9) |
2280 (41.5) |
1073 (37.3) |
1037 (36.5) |
1320 (48.9) |
1243 (46.9) |
Invasive procedures |
Coronary angiography |
During first 10 days, n (%) |
4143 (74.5) |
4072 (74.2) |
2873 (100.0) |
2841 (100.0) |
1270 (47.2) |
1231 (46.6) |
After first 10 days, n (%) |
357 (6.4) |
335 (6.1) |
0 (0) |
0 (0) |
357 (13.3) |
335 (12.7) |
PCI
|
During first 10 days, n (%) |
2590 (46.4) |
2550 (46.4) |
2590 (90.1) |
2550 (89.8) |
0 (0) |
0 (0) |
After first 10 days, n (%) |
279 (5.0) |
291 (5.3) |
11 (0.4) |
3 (0.1) |
268 (9.9) |
288 (10.8) |
CABG
|
During first 10 days, n (%) |
296 (5.3) |
305 (5.5) |
296 (10.3) |
305 (10.7) |
0 (0) |
0 (0) |
After first 10 days, n (%) |
382 (6.8) |
375 (6.8) |
55 (1.9) |
55 (1.9) |
327 (12.1) |
320 (12.0) |